Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
AssigneeUniversity of Rochester
InventorsSteven A. Goldman, Su Wang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a preparation of CD140a/PDGFRα positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM-sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.
Claims8
A method of treating a condition mediated by a loss of myelin or a loss of oligodendrocytes in a human subject, said method comprising:
- providing a population of cells derived from human induced pluripotent stem cells, wherein greater than 30% of said population comprises human oligodendrocyte progenitor cells and said human oligodendrocyte progenitor cells in the population co-express oligodendrocyte transcription factor 2 (OLIG2) and CD140a/platelet derived growth factor receptor α (PDGFRα), and wherein less than 12% of the cells of the population are oligodendrocytes expressing the surface lipid sulfatide recognized by the O4 antibody, and
- administering to the subject the population of provided cells, wherein the condition is a pediatric leukodystrophy and the population is administered to one or more sites of the brain, the brain stem, the spinal cord, or a combination thereof.
Dependencies are inferred from the claim text.